Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519184 | 1.00 | RAB9A (0.49) | RAB9ANPC1L3MBTL1SMN1; SMN2RPS6KB2 | |
| SCHEMBL1107089 | 1.00 | RAB9A (0.49) | RAB9ANPC1L3MBTL1SMN1; SMN2RPS6KB2 | |
| SCHEMBL1519098 | 0.94 | RAB9A (0.49) | RAB9ANPC1L3MBTL1SMN1; SMN2RPS6KB2 | |
| SCHEMBL7437345 | 0.89 | RAB9A (0.50) | RAB9ANPC1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16601605 | 0.87 | RAB9A (0.49) | RAB9ANPC1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13808597 | 0.84 | RAB9A (0.43) | RAB9ANPC1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24121618 | 0.83 | RAB9A (0.46) | RAB9ANPC1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9259508 | 0.82 | CYP3A4 (0.47) | RAB9ANPC1SMN1; SMN2RPS6KB2ALDH1A1 | |
| SCHEMBL7436303 | 0.82 | RAB9A (0.50) | RAB9ANPC1L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1519333 | 0.82 | CYP4F2 (0.50) | RAB9ANPC1L3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | RAB9A 2274/4885NPC1 959/4885L3MBTL1 3894/4885 |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | RAB9A 2274/4885NPC1 959/4885L3MBTL1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.